| Date | Title | Description |
| 19.03.2026 | Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director | Leadership addition expands agency's strategy capabilities amid continued growth
NEW YORK, March 19, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and healthcare, today announced t... |
| 12.12.2025 | ‘This time feels different’: One cannabis investment insider thinks the industry will keep rallying following the latest reports of regulatory changes | - |
| 12.11.2025 | AI-Driven Biotech Iambic Secures Over $100M for Drug Discovery | Iambic, a San Diego AI-driven biotech, secured over $100M in funding. This capital fuels its advanced AI drug discovery platform and expanding clinical pipeline. The company rapidly advances novel therapies, like IAM1363, showing strong ant... |
| 11.11.2025 | Iambic Raises Over $100M in Funding | Iambic, a San Diego, CA-based clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, raised over $100M in funding.
Backers included Abingworth, Alexandria Ventur... |
| 10.11.2025 | Iambic: $100 Million Raised To Advance AI-Discovered Therapeutics And Platform Technologies | Iambic, a clinical-stage life science and technology company headquartered in San Diego, announced that it has raised more than $100 million in an oversubscribed financing round. The round drew participation from a broad group of new and ex... |
| 30.10.2025 | GRAX and CapStorm Join Forces to Protect Enterprises from Data Risk and Loss | Ascendx, the global operator of enterprise software solutions in the Salesforce ecosystem, today announced it has completed its acquisition of GRAX, the U.S.-based Salesforce data management leader. GRAX will now integrate with CapStorm, an... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit
Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion
NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 08.07.2025 | Narcolepsy Network Announces its 38th Annual Conference | A Weekend of Learning, Community and Hope
CAMAS, Wash., July 8, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is delighted to announce its 38th Annual Conference, taking place Friday, October 24 through Sunday, October 26, 2025, at the Roya... |
| 07.07.2025 | Nuevocor Strengthens Board with Appointment of Thierry Abribat | SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board o... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team
NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 13.12.2024 | Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases | Angitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ... |
| 24.11.2024 | Navigating the Sleep Science Frontier: A New Era for Hypersomnolence Treatment | Sleep is a complex puzzle. For many, it’s a sanctuary. For others, it’s a battleground. Central disorders of hypersomnolence, like narcolepsy and idiopathic hypersomnia, turn sleep into a foe. These conditions cause excessive daytime sleepi... |
| 18.11.2024 | State-of-the-science webinar will explore narcolepsy and hypersomnia | Sleep Research Society Foundation
Free webinar from the Sleep Research Society Foundation is Monday, Dec. 2.
DARIEN, Ill., Nov. 18, 2024 /PRNewswire-PRWeb/ -- The Sleep Research Society Foundation is hosting a state-of-the-science webinar, ... |
| 15.10.2024 | Датская компания Lundbeck приобретает американского разработчика лекарства от эпилепсии за $2,6 млрд | Сделка расширяет портфель услуг копенгагенской компании Lundbeck по лечению неврологических заболеваний, таких как болезнь Паркинсона, мигрень и болезнь Альцгеймера.
Lundbeck прогнозирует потенциальный мировой пик продаж в размере $1,5–2 мл... |
| 15.10.2024 | The Data Leader's Role in Measuring and Communicating the Value of Real-world Data, Upcoming Webinar Hosted by Xtalks | www.optum.com/en/business/life-sciences.html
In this free webinar, learn about conceptual and tangible ways to approach the real-world data value conversation. Attendees will gain insights into the breadth of the challenges that many are fa... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 08.07.2024 | Ligand to Acquire Apeiron Biologics, for $100M | Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-b... |
| 13.06.2024 | Global Gene's RARE-X and Sleep Consortium Launch Sleep Data Collection Initiative to Accelerate Development of Therapies | Global Genes
The Sleep Data Collection Initiative, the first consortium on the RARE-X platform for the collection and sharing of patient-owned data, brings together patient advocacy organizations, researchers, and drug developers looking to... |
| 24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatment of multiple disease areas
BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) b... |
| 07.04.2022 | NASDAQ Roundtable: $JAZZ signs Agreement with $HOWL Today: Is $AVCO a Leader in Therapeutics next? Avalon (NASDAQ: AVCO) | $AVCO Therapeutics to fight Cancer
AVCO Rings NASDAQ Bell
Werewolf Therapeutics logo
Werewolf Therapeutics
$AVCO NASDAQ
$AVCO a Leading global developer of cell-based Technologies & Therapeutics be next? Avalon Globocare Corp. (NASDAQ: ... |
| 10.01.2022 | Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader | DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5 billion in rev... |
| 15.12.2021 | Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor | DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZ... |
| 03.08.2021 | Jazz Pharmaceuticals : Announces Second Quarter 2021 Financial Results | DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021.
"As we enter what we expect to be... |
| 13.07.2021 | Jazz Pharmaceuticals : Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021 | DUBLIN, July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Rylaze™ (asparaginase erwin... |
| 30.06.2021 | Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | |
| 17.06.2021 | JAZZ PHARMACEUTICALS PLC
Jazz Pharmaceuticals : Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc | DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company acquired on May 5, 2021.
"We expec... |
| 09.06.2021 | JAZZ PHARMACEUTICALS PLC
Jazz Pharmaceuticals : Presents 18 Abstracts in Sleep Medicine at SLEEP 2021 | DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th... |
| 05.05.2021 | GW PHARMACEUTICALS PLC
GW Pharmaceuticals : Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc | DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization ... |
| 20.04.2021 | JAZZ PHARMACEUTICALS PLC
JAZZ PHARMACEUTICALS PLC : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statem... | Item 1.01 Entry into a Material Definitive Agreement.
On April 20, 2021, Jazz Pharmaceuticals Public Limited Company ("Jazz," the "Company," "we" or "our"), as guarantor, and certain of its wholly-own... |
| 20.04.2021 | GW PHARMACEUTICALS PLC
GW PHARMACEUTICALS PLC : Other Events (form 8-K) | Item 8.01 Other Events.
As previously disclosed, on February 3, 2021, GW Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales ("GW"), entered into a transaction agreement with Jazz Pharmac... |
| 23.02.2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | |
| 23.02.2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.
"In 2020, we made meaningful progres... |
| 17.02.2021 | Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference | |
| 03.02.2021 | Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader | |
| 14.08.2016 | Major drug partnership aims to develop new cancer drug | Helsinn assumes worldwide development costs and marketing rights for MEI Pharma’s drug and gains a foothold in the cancer therapeutics market. MEI receives $20 million in near-term payments with the potential for $444 million in various mil... |
| 18.10.2007 | Life sciences briefing: Thursday, Oct. 18, 2007 | Featured companies: American Oriental Bioengineering, Guangxi Boke, Inspired Technologies, Nanosphere, Patton Medical Devices
UPDATED: Expanded items on Nanosphere and Patton Medical Devices.
Molecular-diagnostics firm Nanosphere sets IPO r... |
| 26.07.2007 | Biotech financing: Will ImaRx break the IPO slump? | (UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and ... |
| 31.05.2007 | Jazz Pharma takes it on the chin, raises less-than-expected $108M in IPO | Reuters is reporting that Jazz Pharmaceuticals, maker of the controversial drug Xyrem, priced its six million IPO shares at $18 apiece — roughly 30% below its earlier, most optimistic hopes. Just this morning, Jazz lowered its expected rang... |
| 31.05.2007 | Jazz slashes expected IPO price, follows “date rape” controversy | Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that hoped to raise $179.4 million in an IPO, has collided with reality.
The Palo Alto, Calif. company today slashed its expected IPO price by a fifth.
We’ve writ... |
| 31.05.2007 | Jazz Pharma ratchets down IPO hopes amid drug controversy | (UPDATED: See below.) Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that had hoped to raise $179.4 million in an IPO, has collided with reality.
The company today lowered its expected IPO take to a maximum of... |
| 18.05.2007 | Amicus Therapeutics aims for potentially disruptive $92M IPO | Amicus Therapeutics, a Cranbury, N.J., developer of drugs to treat rare genetic diseases, said it plans to raise as much as $92 million in an IPO — money that would fund its pursuit of new drugs for rare genetic diseases, a strategy could b... |
| 17.05.2007 | Jazz Pharmaceuticals shoots for $179M IPO with me-too drugs | Jazz Pharmaceuticals, a Palo Alto, Calif., outfit that licenses and acquires drugs from other companies, said it hopes to raise up to $179.4 million in a 6.9 million share offering — all based on a stable of unexciting drug retreads.
Accord... |
| 17.05.2007 | Jazz’s audacious IPO | Jazz Pharmaceuticals, a Palo Alto, Calif. drug company that launched four years ago, and raised an eye-popping $250 million to buy existing drug products from other companies, has just upgraded its IPO plans to raise up to $179 million.
Tal... |
| - | Major drug partnership aims to develop new cancer drug | A recent cancer partnership worth hundreds of millions of dollars aims to develop a drug to contend with acute myeloid leukemia.
San Diego-based MEI Pharma has inked a deal with Swiss firm Helsinn to develop and market its HDAC (the class o... |